Paul Tudor Jones's PTGX Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 7,718 shares of Protagonist Therapeutics, Inc. (PTGX) worth $674,090, representing 0.00% of the portfolio. First purchased in 2022-Q3, this medium-term investment has been held for 13 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in PTGX, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 42,583 shares. Largest reduction occurred in Q2 2025, reducing 42,583 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Protagonist Therapeutics (PTGX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Protagonist Therapeutics (PTGX) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +7,718 | New Buy | 7,718 | $87.34 |
| Q2 2025 | -42,583 | Sold Out | 0 | $0.00 |
| Q1 2025 | +42,583 | New Buy | 42,583 | $48.36 |
| Q4 2024 | -13,858 | Sold Out | 0 | $0.00 |
| Q3 2024 | +13,858 | New Buy | 13,858 | $45.00 |
| Q2 2024 | -22,510 | Sold Out | 0 | $0.00 |
| Q1 2024 | -6,276 | Reduce 21.80% | 22,510 | $28.93 |
| Q4 2023 | +28,786 | New Buy | 28,786 | $22.93 |
| Q3 2023 | -33,338 | Sold Out | 0 | $0.00 |
| Q2 2023 | -4,002 | Reduce 10.72% | 33,338 | $27.62 |
| Q1 2023 | +37,340 | New Buy | 37,340 | $0.02 |
| Q4 2022 | -24,332 | Sold Out | 0 | $0.00 |
| Q3 2022 | +24,332 | New Buy | 24,332 | $8.43 |
Paul Tudor Jones's Protagonist Therapeutics Investment FAQs
Paul Tudor Jones first purchased Protagonist Therapeutics, Inc. (PTGX) in Q3 2022, acquiring 24,332 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Protagonist Therapeutics, Inc. (PTGX) for 13 quarters since Q3 2022.
Paul Tudor Jones's largest addition to Protagonist Therapeutics, Inc. (PTGX) was in Q1 2025, adding 42,583 shares worth $2.06 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 7,718 shares of Protagonist Therapeutics, Inc. (PTGX), valued at approximately $674,090.
As of the Q4 2025 filing, Protagonist Therapeutics, Inc. (PTGX) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Protagonist Therapeutics, Inc. (PTGX) was 42,583 shares, as reported at the end of Q1 2025.